At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Grazoprevir/Elbasvirdrug
Likely dose
Grazoprevir/Elbasvir 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4: Efficacy and Tolerability of Grazoprevir 100mg/Elbasvir 50mg During 8 Weeks
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba·interventional·Posted Sep 1, 2016·Updated Jan 29, 2020
In Brief
A Phase 2 clinical trial evaluating Grazoprevir/Elbasvir for Acute Hepatitis C and HIV. Completed, enrolled 30 participants across 6 sites.
Detailed Summary
The purpose of this study is to assess the rate of sustained virological response (SVR) 12 weeks after 8-week oral treatment with grazoprevir 100mg/elbasvir 50mg (MRK-combo) in patients with acute hepatitis C genotype1 or 4.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Hepatitis C, HIV
CountriesFrance
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartMay 2017
Primary CompletionDec 2018
Study CompletionSep 2019
TodayJul 2026
First PostedSep 1, 2016
Enrollment StartMay 31, 2017
Primary CompletionDec 31, 2018
Study CompletionSep 16, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.8 years ago
Interventions
Grazoprevir/Elbasvirdrug
Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks